Skip to main content
Premium Trial:

Request an Annual Quote

Genedata Joins Alliance Developing High-throughput Phenotype-Genotype Platform

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genedata today announced its participation in an industry-led consortium to develop a high-throughput phenotype-genotype platform for the identification of complex genetic effects.

As part of its participation, the Genedata Selector software system will be used for the analysis and management of the biologically relevant production phenotype strains and processes.

The project, called the Integrated Phenotype-Genotype project, is integrating high-throughput phenotyping and genotyping platforms with the resulting platform based on Genedata Selector, which supports industrial biotechnology strain optimization and next-generation sequencing technologies.

"The platform uses parallelized, multiplexed phenotype assays to support the systematic processing, storage, and mining of large volumes of data," Genedata said, adding that the main applications for the platform are in industrial biotech strain and process development.

IPG is funded by the German Federal Ministry of Education and Research. Members of IPG, which include Evonik Industries, GATC, and the Bielefeld University Center of Biotechnology, are contributing intellectual property and technologies to the development of the platform.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.